Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Kineta Reports First Quarter 2023 Financial Results and
Dosed First Patient in Phase 1/2 Clinical Study of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Kineta
Kineta Reports Full Year 2022 Financial Results and
Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for…
Kineta to Present VISTA Biomarker Data at AACR Annual
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc.…
Kineta to Present KVA12123 VISTA Blocking Immunotherapy
SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today…
- Advertisement -
Kineta to Participate in JMP Securities Hematology and
SEATTLE, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today…